Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1994 2
1997 1
1998 4
1999 2
2000 1
2001 3
2002 2
2003 2
2004 3
2005 3
2006 3
2007 3
2008 4
2009 2
2010 1
2013 3
2014 8
2015 6
2016 4
2017 12
2018 3
2019 16
2020 10
2021 8
2022 3
2023 4
2024 5

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

104 results

Results by year

Filters applied: . Clear all
Page 1
Pembrolizumab alone or combined with chemotherapy versus chemotherapy as first-line therapy for advanced urothelial carcinoma (KEYNOTE-361): a randomised, open-label, phase 3 trial.
Powles T, Csőszi T, Özgüroğlu M, Matsubara N, Géczi L, Cheng SY, Fradet Y, Oudard S, Vulsteke C, Morales Barrera R, Fléchon A, Gunduz S, Loriot Y, Rodriguez-Vida A, Mamtani R, Yu EY, Nam K, Imai K, Homet Moreno B, Alva A; KEYNOTE-361 Investigators. Powles T, et al. Among authors: geczi l. Lancet Oncol. 2021 Jul;22(7):931-945. doi: 10.1016/S1470-2045(21)00152-2. Epub 2021 May 26. Lancet Oncol. 2021. PMID: 34051178 Clinical Trial.
Cabozantinib versus Everolimus in Advanced Renal-Cell Carcinoma.
Choueiri TK, Escudier B, Powles T, Mainwaring PN, Rini BI, Donskov F, Hammers H, Hutson TE, Lee JL, Peltola K, Roth BJ, Bjarnason GA, Géczi L, Keam B, Maroto P, Heng DY, Schmidinger M, Kantoff PW, Borgman-Hagey A, Hessel C, Scheffold C, Schwab GM, Tannir NM, Motzer RJ; METEOR Investigators. Choueiri TK, et al. Among authors: geczi l. N Engl J Med. 2015 Nov 5;373(19):1814-23. doi: 10.1056/NEJMoa1510016. Epub 2015 Sep 25. N Engl J Med. 2015. PMID: 26406150 Free PMC article. Clinical Trial.
Phase III Study Comparing a Reduced Dose of Cabazitaxel (20 mg/m2) and the Currently Approved Dose (25 mg/m2) in Postdocetaxel Patients With Metastatic Castration-Resistant Prostate Cancer-PROSELICA.
Eisenberger M, Hardy-Bessard AC, Kim CS, Géczi L, Ford D, Mourey L, Carles J, Parente P, Font A, Kacso G, Chadjaa M, Zhang W, Bernard J, de Bono J. Eisenberger M, et al. Among authors: geczi l. J Clin Oncol. 2017 Oct 1;35(28):3198-3206. doi: 10.1200/JCO.2016.72.1076. Epub 2017 Aug 15. J Clin Oncol. 2017. PMID: 28809610 Clinical Trial.
[Immunotherapy in advanced urothelial cancer].
Géczi L, Dienes T, Küronya Z, Maráz A, Nagyiványi K. Géczi L, et al. Magy Onkol. 2021 Dec 7;65(4):339-346. Epub 2021 Nov 10. Magy Onkol. 2021. PMID: 34874365 Free article. Review. Hungarian.
[Immunotherapy of renal cell cancer].
Géczi L, Nagyiványi K, Maráz A. Géczi L, et al. Magy Onkol. 2017 Jun 6;61(2):126-131. Epub 2017 Apr 23. Magy Onkol. 2017. PMID: 28585613 Free article. Review. Hungarian.
[The role of steroids in oncological practice].
Küronya Z, Géczi L, Gyergyay F, Bíró K. Küronya Z, et al. Among authors: geczi l. Orv Hetil. 2017 Oct;158(42):1651-1657. doi: 10.1556/650.2017.30879. Orv Hetil. 2017. PMID: 29037061 Review. Hungarian.
[Immunotherapy in the treatment of genitourinary cancers].
Géczi L, Ladányi A, Vajdics T, Küronya Z, Bíró K, Gyergyay F, Martin T, Nagyiványi K. Géczi L, et al. Magy Onkol. 2016 Mar 2;60(1):41-5. Epub 2016 Feb 8. Magy Onkol. 2016. PMID: 26934350 Free article. Review. Hungarian.
104 results